0000000000706843

AUTHOR

Josep Julve

0000-0002-6531-2246

showing 2 related works from this author

Fatty Liver and Fibrosis in Glycine N-Methyltransferase Knockout Mice Is Prevented by Nicotinamide

2010

Deletion of glycine N-methyltransferase (GNMT), the main gene involved in liver S-adenosylmethionine (SAM) catabolism, leads to the hepatic accumulation of this molecule and the development of fatty liver and fibrosis in mice. To demonstrate that the excess of hepatic SAM is the main agent contributing to liver disease in GNMT knockout (KO) mice, we treated 1.5-month-old GNMT-KO mice for 6 weeks with nicotinamide (NAM), a substrate of the enzyme NAM N-methyltransferase. NAM administration markedly reduced hepatic SAM content, prevented DNA hypermethylation, and normalized the expression of critical genes involved in fatty acid metabolism, oxidative stress, inflammation, cell proliferation, …

Liver CirrhosisNiacinamidemedicine.medical_specialtyPathologyS-AdenosylmethionineCirrhosisGene ExpressionGlycine N-MethyltransferaseBiologyArticleLiver diseasechemistry.chemical_compoundMiceFibrosisInternal medicinemedicineAnimalsRas signalingMice KnockoutDNA methylationHepatologyFatty acid metabolismFatty livermedicine.diseaseGlycine N-methyltransferaseFatty LiverEndocrinologyJAK/STAT signalingchemistryGNMThepatocytesHepatic fibrosisGene Deletion
researchProduct

Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients

2014

Abstract HDL-increasing drugs such as fenofibrate and niacin have failed to decrease the cardiovascular risk in patients with type 2 diabetes. Drug-mediated quantitative and qualitative HDL modifications could be involved in these negative results. To evaluate the quantitative and qualitative effects of niacin and fenofibrate on HDL in patients with type 2 diabetes, a prospective, randomised controlled intervention trial was conducted. Thirty type 2 diabetic patients with low HDL were randomised to receive either fenofibrate (FFB) or niacin + laropiprant (ERN/LPR) as an add-on to simvastatin treatment for 12 weeks according to a crossover design. At the basal point and after each interventi…

MaleSimvastatinIndolesTime FactorsType 2 diabetesHigh-Density Lipoproteins Pre-betaAntioxidantsBasal (phylogenetics)chemistry.chemical_compoundFenofibrateProspective StudiesHypolipidemic AgentsFenofibrateMiddle AgedOxidantsPON1Up-RegulationTreatment OutcomeDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineNiacinmedicine.drugAdultmedicine.medical_specialtyNiacinbehavioral disciplines and activitiesInternal medicinemedicineHumansMetabolomicsParticle SizeAgedDyslipidemiasbusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesmedicine.diseaseCrossover studyCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2chemistrySpainSimvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersAtherosclerosis
researchProduct